{'fraction_non_alphanumeric': 0.02666666666666667, 'fraction_numerical': 0.0, 'mean_word_length': 4.646616541353383, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ADAP treatment-access emergency--interview with William Arnold, ADAP Working Group. Interview by John S. James.


 The AIDS Drug Assistance Program (ADAP), which is supported by Ryan White money and pays for drugs for people without private insurance, is facing a cash crisis as the AIDS treatment community moves toward more aggressive and expensive combination anti-HIV therapy. William Arnold, Co-Chair of the ADAP Working Group, discusses what needs to be done to improve ADAP funding and expand treatment to patients. The funding problem is showing up in many States, very few of which have even added protease inhibitors to their ADAP formularies. Cost concerns and access to treatment is becoming a central issue for people with HIV and AIDS.
